Pharmaceutical giant Novo Nordisk (NVO) inks a $2.2 billion deal with biotech company Septerna (SEPN) to develop a GLP-1 weight-loss drug in the form of an oral pill. Septerna's stock is skyrocketing by over 60% in Wednesday's pre-market session (at the time of this video's posting).
Yahoo Finance senior health reporter Anjalee Khemlani outlines the latest news on this deal and the details of this agreement.
To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.
